Opus Genetics, a trailblazer in the field of ophthalmic biopharmaceutical innovation, is proud to announce a significant funding milestone, raising $20,000,000 in our latest financing round. This new capital injection marks a pivotal moment for our company as we build on the exciting foundations laid by Ocuphire Pharma, Inc. and our own commitment to developing transformative therapies. By combining the pioneering spirit and expertise of both former entities under the united Opus Genetics banner (Nasdaq: IRD), we stand at the forefront of clinical-stage development, focused on advancing gene therapies that target inherited retinal diseases (IRDs) and other retinal and refractive disorders. The funds will be strategically deployed to accelerate our research and development efforts, enhance clinical trial capabilities, and expand our state-of-the-art biopharmaceutical infrastructure. With an unwavering mission to innovate, improve efficiency, and ensure sustainability in our processes, we are poised to bring groundbreaking treatments from the laboratory to the clinic. These therapies are designed to not only halt the progression of debilitating retinal conditions but also restore vision and improve quality of life for patients whose options have been limited until now. Our robust pipeline reflects a deep commitment to scientific excellence and patient-centric solutions, and this funding injection further reinforces our dedication to transforming the landscape of ophthalmic care. As we continue to strengthen our clinical and operational capabilities, Opus Genetics remains focused on forging new paths in gene therapy, ultimately creating a brighter future for millions impacted by retinal diseases worldwide.
Illuminating the Future: Opus Genetics Secures $20M to Transform Ophthalmic Gene Therapy
Recently funded 路 $20.0MGene Therapy
Get the full Opus Genetics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
